Alluvi, known as BI 4744, represents a notable advance in obesity treatment. This dual activator targeting both GLP-1 and GIP sites demonstrates impressive effectiveness in patient studies, potentially outperforming https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/